Stewart Fisher - Mar 7, 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Scientific Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Mar 7, 2024
Transactions value $
$0
Form type
4
Date filed
3/8/2024, 07:26 PM
Previous filing
Feb 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Disposed to Issuer $0 -95K -100% $0.00* 0 Mar 7, 2024 Common Stock 95K $45.54 Direct F1, F2
transaction CCCC Stock Option (Right to Buy) Award $0 +95K $0.00 95K Mar 7, 2024 Common Stock 95K $19.00 Direct F1, F2
transaction CCCC Stock Option (Right to Buy) Disposed to Issuer $0 -118K -100% $0.00* 0 Mar 7, 2024 Common Stock 118K $22.71 Direct F1, F3
transaction CCCC Stock Option (Right to Buy) Award $0 +118K $0.00 118K Mar 7, 2024 Common Stock 118K $19.00 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2 This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021.
F3 The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.